Otto Simonsson

Otto Simonsson

Auto-generated profile, based on publicly available information

Otto Simonsson

Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 January 2022 in PLOS Digital Health
Verified
Journal Article
Open access
PDF file
SGSimon B. Goldberg
Simon B. Goldberg
SLSin U Lam
Sin U Lam
OSOtto Simonsson
Otto Simonsson
JTJohn Torous
John Torous
SSShufang Sun
Shufang Sun
Mobile phone-based interventions have been proposed as a means for reducing the burden of disease associated with mental illness. While numerous randomized controlled trials and meta-analyses have investigated this possibility, evidence remains unclear. We conducted a systematic meta-review of meta-analyses examining mobile phone-based interventions tested in randomized controlled trials. We synthesized results from 14 meta-analyses representing 145 randomized controlled trials and 47,940 participants. We identified 34 effect sizes representing unique pairings of participants, intervention, comparisons, and outcome (PICO) and graded the strength of the evidence as using umbrella review methodology. We failed to find convincing evidence of efficacy (i.e., n > 1000, p < 10−6, I2 < 50%, absence of publication bias); publication bias was rarely assessed for the representative effect sizes. Eight effect sizes provided highly suggestive evidence (i.e., n > 1000, p < 10−6), including smartphone interventions outperforming inactive controls on measures of psychological symptoms and quality of life (ds = 0.32 to 0.47) and text message-based interventions outperforming non-specific controls and active controls for smoking cessation (ds = 0.31 and 0.19, respectively). The magnitude of effects and strength of evidence tended to diminish as comparison conditions became more rigorous (i.e., inactive to active, non-specific to specific). Four effect sizes provided suggestive evidence, 14 effect sizes provided weak evidence, and eight effect sizes were non-significant. Despite substantial heterogeneity, no moderators were identified. Adverse effects were not reported. Taken together, results support the potential of mobile phone-based interventions and highlight key directions to guide providers, policy makers, clinical trialists, and meta-analysts working in this area.

18 October 2024 in Science
Verified
Journal Article
Closed access
JVJan G. Voelkel
Jan G. Voelkel
MSMichael N. Stagnaro
Michael N. Stagnaro
JCJames Y. Chu
James Y. Chu
SPSophia L. Pink
Sophia L. Pink
JMJoseph S. Mernyk
Joseph S. Mernyk
RWRobb Willer
Robb Willer
Scholars warn that partisan divisions in the mass public threaten the health of American democracy. We conducted a megastudy ( n = 32,059 participants) testing 25 treatments designed by academics and practitioners to reduce Americans’ partisan animosity and antidemocratic attitudes. We find that many treatments reduced partisan animosity, most strongly by highlighting relatable sympathetic individuals with different political beliefs or by emphasizing common identities shared by rival partisans. We also identify several treatments that reduced support for undemocratic practices—most strongly by correcting misperceptions of rival partisans’ views or highlighting the threat of democratic collapse—which shows that antidemocratic attitudes are not intractable. Taken together, the study’s findings identify promising general strategies for reducing partisan division and improving democratic attitudes, shedding theoretical light on challenges facing American democracy.

30 January 2023 in Journal of Affective Disorders
Verified
Journal Article
Open access
OSOtto Simonsson
Otto Simonsson
PHPeter S. Hendricks
Peter S. Hendricks
RCRichard Chambers
Richard Chambers
WOWalter Osika
Walter Osika
SGSimon B. Goldberg
Simon B. Goldberg
Previous studies have investigated challenging, difficult, or distressing classic psychedelic experiences, but little is known about the prevalence and associations of such experiences. Using nationally representative data of the US adult population (N = 2822), this study examined the prevalence and associations of challenging, difficult, or distressing experiences using classic psychedelics, in a subsample of respondents who reported lifetime classic psychedelic use (n = 613). Of the 613 respondents who reported lifetime classic psychedelic use, the majority of them (59.1 %) had never had a challenging, difficult, or distressing experience using a classic psychedelic, but 8.9 % of respondents reported functional impairment that lasted longer than one day as a result of such experiences. Notably, 2.6 % reported seeking medical, psychiatric, or psychological assistance in the days or weeks following their most challenging, difficult, or distressing classic psychedelic experience. In covariate-adjusted regression models, co-use of lithium, co-use of other mood stabilizers, and six set and setting variables (no preparation, disagreeable physical environment, negative mindset, no psychological support, dose was too large, major life event prior to experience) were associated with the degree of difficulty; and co-use of lithium, co-use of other mood stabilizers, and three set and setting variables (negative mindset, no psychological support, major life event prior to experience) were associated with overall risk of harm. In summary, this study provides insight into the prevalence and associations of challenging, difficult, or distressing classic psychedelic experiences. The findings broadly correspond with findings from previous studies and can inform harm reduction efforts and future experimental research designs.

9 March 2021 in Journal of Psychopharmacology
Verified
Journal Article
Open access
PDF file
OSOtto Simonsson
Otto Simonsson
JSJames D Sexton
James D Sexton
PHPeter S Hendricks
Peter S Hendricks
Background: In recent years, there has been significant research on the mental health effects of classic psychedelic use, but there is very little evidence on how classic psychedelics might influence physical health. Aims: The purpose of the present study was to investigate the associations between lifetime classic psychedelic use and markers of physical health. Methods: Using data from the National Survey on Drug Use and Health (2015-2018) with 171,766 (unweighted) adults aged 18 or above in the United States, the current study examined the associations between lifetime classic psychedelic use and three markers of physical health (self-reported overall health, body mass index, and heart condition and/or cancer in the past 12 months) while controlling for a range of covariates. Results: Respondents who reported having tried a classic psychedelic at least once in their lifetime had significantly higher odds of greater self-reported overall health and significantly lower odds of being overweight or obese versus having a normal weight. The association between lifetime classic psychedelic use and having a heart condition and/or cancer in the past 12 months approached conventional levels of significance, with lower odds of having a heart condition and/or cancer in the past 12 months for respondents who had tried a classic psychedelic at least once. Conclusion: The results of the present study suggest that classic psychedelics may be beneficial to physical health. Future research should investigate the causal effects of classic psychedelics on physical health and evaluate possible mechanisms.

9 February 2023 in Nature Human Behaviour
Verified
Journal Article
Closed access
PDF file
TCThe Forecasting Collaborative
The Forecasting Collaborative
IGIgor Grossmann
Igor Grossmann
ARAmanda Rotella
Amanda Rotella
CHCendri A. Hutcherson
Cendri A. Hutcherson
KSKonstantyn Sharpinskyi
Konstantyn Sharpinskyi
TWTom Wilkening
Tom Wilkening

13 July 2021 in Scientific Reports
Verified
Journal Article
Open access
PDF file
OSOtto Simonsson
Otto Simonsson
WOWalter Osika
Walter Osika
RCRobin Carhart-Harris
Robin Carhart-Harris
PHPeter S. Hendricks
Peter S. Hendricks
The objective of the current study was to investigate the associations between lifetime classic psychedelic use and cardiometabolic diseases. Using data from the National Survey on Drug Use and Health (2005–2014), the present study examined the associations between lifetime classic psychedelic use and two types of cardiometabolic disease: heart disease and diabetes. Respondents who reported having tried a classic psychedelic at least once in their lifetime had lower odds of heart disease in the past year (adjusted odds ratio (aOR) = 0.77 (0.65–0.92), p = .006) and lower odds of diabetes in the past year (adjusted odds ratio (aOR) = 0.88 (0.78–0.99), p = .036). Classic psychedelic use might be beneficial for cardiometabolic health, but more research is needed to investigate potential causal pathways of classic psychedelics on cardiometabolic diseases.